DWTX DWTX
Company Profile ↓Company Overview
DWTX (DWTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -62.35% |
| 6 Months: | -39.60% |
| 3 Months: | +27.08% |
| 1 Month: | +27.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)71.41 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 76.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -382.55K | -538.38K | -2.66M | -3.06M | -4.28M | -4.11M | -3.96M | -3.67M | -2.59M | -1.56M | -1.48M | -1.27M | -1.31M | -1.07M | -2.30M | -4.43M | -3.92M | -15.81M | -5.08M |
| Net Income | -466.55K | -654.59K | -2.72M | -3.06M | -4.28M | -4.11M | -3.96M | -3.67M | -2.58M | -1.52M | -1.44M | -1.24M | -1.29M | -1.05M | -2.28M | -10.92M | -3.81M | -15.74M | -4.99M |
| Diluted EPS | - | - | - | -0.37 | -0.51 | -0.49 | -0.48 | -0.44 | -0.28 | -0.08 | -0.08 | -1.62 | -1.68 | -1.15 | -2.05 | -8.45 | -1.99 | -8.20 | -0.15 |
| R&D Expense | 30.54K | 23.32K | 108.09K | 1.71M | 3.21M | 2.96M | 2.77M | 2.41M | 1.62M | 497.71K | 557.84K | 374.20K | 343.72K | 336.08K | 535.16K | 2.44M | 2.57M | 14.52M | 2.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -10.01M | -15.64M | -12.32M | -5.45M | -12.23M | -27.97M |
| Net Income | -10.35M | -15.96M | -12.25M | -5.30M | -12.35M | -34.26M |
| Diluted EPS | -2.10 | -1.92 | -1.11 | -7.05 | -12.52 | -7.13 |
| R&D Expense | 194.01K | 10.80M | 8.07M | 1.73M | 3.53M | 21.87M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 31.47M | 15.78M | 8.37M | 4.17M | 94.31M | 90.17M |
| Total Equity | -5.02M | 29.94M | 14.50M | 7.33M | 3.81M | -10.12M | 74.90M |
| Cash & Equivalents | - | 29.80M | 14.01M | 7.03M | 3.32M | 14.85M | 6.52M |
| Total Liabilities | - | 1.53M | 1.28M | 1.04M | 358.55K | 30.03M | 15.27M |
| Current Liabilities | - | 1.53M | 1.28M | 1.04M | 358.55K | 3.18M | 3.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.90M | -15.69M | -11.47M | -4.87M | -8.79M | -15.62M |
| Investing Cash Flow | - | - | - | - | 3.76M | - |
| Financing Cash Flow | 33.38M | -97.60K | 4.49M | 1.16M | 16.70M | 7.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -34.6% | -110.1% | -167.2% | -139.1% | 122.0% | -45.7% |
| ROCE % | -33.4% | -107.9% | -168.1% | -143.1% | -13.4% | -32.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DWTX
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
- Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated -ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasd…
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, …
Chemotherapy-Induced Peripheral Neuropathy Market to Witness Significant Growth at a CAGR of 14.2% During the Forecast Period (2026-2036) as Novel Therapies Enter Late-Stage Development | DelveInsight
Recently published Chemotherapy-Induced Peripheral Neuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chemotherapy-induced peripheral neuropathy emerging drugs, market share of individua…
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron® 4-week CINP Phase 2b study are n…
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Anno…
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first qua…
DWTX — Frequently Asked Questions
What is the current share price of DWTX?
As of 2026-08-05 17:25 PDT, DWTX trades at $1.83 on NASDAQ/NYSE. Its 52-week range is $1.34 to $7.91.
What is the P/E ratio of DWTX?
DWTX trades at a trailing price-to-earnings (P/E) ratio of -0.26.
What is the return on equity (ROE) of DWTX?
DWTX has a return on equity (ROE) of -45.74%. Its return on capital employed (ROCE) is -32.11%.
Is DWTX a good stock to buy?
This page provides a data-driven analysis of DWTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.